Clinigen Group and Cumberland Pharmaceuticals have announced that Cumberland has launched Ethyol (amifostine) for injection in the U.S. Ethyol is a key global brand within Clinigen's speciality pharmaceuticals division and is the first product that Cumberland has licensed from Clinigen under an exclusive strategic alliance entered into in 2015.
The US launch represents an important milestone in ensuring patients have the best opportunity to be treated with Ethyol, should they need it.
Ethyol is an FDA approved, hospital-based cytoprotective drug indicated to reduce the incidence of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer.
Xerostomia can significantly impact the daily lives of head and neck cancer patients during their survivorship. Ethyol provides an important option for patients and their physicians to consider prior to starting radiotherapy treatment. It also reduces the cumulative renal toxicity for women with ovarian cancer from their cisplatin chemotherapy, allowing them the best chance of completing their treatment course.
Cumberland will be responsible for all hospital sales, promotion, distribution, and medical support of Ethyol in the US.
In preparation for the product's launch, Cumberland's sales and medical organisation has completed a comprehensive training program. The company has also stocked the product at wholesalers serving hospitals nationwide, and recently introduced a product website to support healthcare professionals by providing information about Ethyol.
(LON:CLIN) Clinigen Group share price was +7p at 690p